'Black sheep protein' key to cancer cell death

Cancer Research UK

A neglected member of an important family of proteins could boost the effectiveness of an exciting new group of cancer drugs - reveals a study in Cancer Cell* today (Monday).

HSP90 inhibitors are a new group of drugs that work by stopping the activity of many cancer-causing proteins. After years of research, scientists found that silencing the HSP90 protein stopped tumours growing.

But now researchers funded by Cancer Research UK, and based at The Institute of Cancer Research, have found that inhibiting another protein in the same family - HSP70 - can help HSP90 inhibitors stop the growth of cancer cells and can also kill off tumour cells very effectively even without HSP90 drugs.

Their findings have led the researchers to believe that new drugs that inhibit HSP70 could be developed and used either on their own or in combination with HSP90 inhibitors - potentially providing more effective treatments that target cancer cells and leave healthy cells unharmed.

Lead author, Professor Paul Workman, based at the Cancer Research UK Centre for Cancer Therapeutics at The Institute of Cancer Research in Sutton, said: "HSP70 proteins haven't received as much attention, and were the neglected members of the HSP family of proteins. When we silenced these proteins our results were really surprising."

The team studied the effects of silencing HSP proteins in bowel and ovarian cancer cells. They found that knocking out two particular proteins - HSC70 and HSP72 which are forms of the HSP70 protein - caused cell death only in cancer cells.

Professor Workman continued: "Most of the recent research in this field has focussed heavily on inhibiting HSP90, which was thought to be the most crucial protein involved in making sure cancer-causing proteins were kept intact. What's most exciting is that not only can knocking out both HSC70 and HSP72 eliminate the dangerous cancer-causing proteins, but in addition this approach can kill cancer cells much very more effectively than normal cells.

"We hope that in the future, drugs can be designed to inhibit the HSP70 proteins, following on from those that already block HSP90, to stop tumour growth and kill off cancer cells."

Professor Herbie Newell, Cancer Research UK's executive director of clinical and translational research, said: "This is a great example of why cancer research is such an exciting field. There are constantly new discoveries being made that challenge our current ways of thinking and that open up new doors for developing better and more targeted therapies.

"HSP90 inhibitors are currently being tested in clinical trials on patients with breast and other cancers. We hope this new research on HSP70 will be translated into exciting drug discoveries in the future."

ENDS

For media enquiries please contact the Cancer Research UK press office on 020 7061 8300 or, out-of-hours, the duty press officer on 07050 264 059.

Notes to Editor

* Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis. Powers et al. 2008. Cancer Cell.

About Chaperones/Heat Shock Proteins

The HSP (heat shock protein) family belong to a group of proteins known as molecular chaperones. They play an important role in normal cells, helping other proteins to fold correctly, become activated or degraded, and ensuring that they are able to carry out their vital functions in the body properly. In addition, molecular chaperones are also important in helping the cell deal with stresses, including heat. Cancer is a stressed state as a result of the abundance of overexpressed and activated oncogene products and the pressures to survive in the hostile environment of a tumour. So cancer cells are more dependent on molecular chaperones than are normal cells and inhibiting the chaperone function provides the basis for a differential effect on cancer versus normal cells.

About The Institute of Cancer Research

The Institute of Cancer Research is Europe's leading cancer research centre with expert scientists working on cutting edge research. It was founded in 1909 to carry out research into the causes of cancer and to develop new strategies for its prevention, diagnosis, treatment and care. For more information visit the ICRhomepage. The Institute is a charity that relies on voluntary income. The Institute is one of the world’s most cost-effective major cancer research organisations with over 95p in every £ of total income directly supporting research.

About Cancer Research UK

  • Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.
  • Cancer Research UK carries out world-class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancer.
  • Cancer Research UK ensures that its findings are used to improve the lives of all cancer patients.
  • Cancer Research UK helps people to understand cancer, the progress that is being made and the choices each person can make.
  • Cancer Research UK works in partnership with others to achieve the greatest impact in the global fight against cancer.
  • For further information about Cancer Research UK's work or to find out how to support the charity, please call 020 7121 6699 or visit our homepage.